Fintel · Oct 23, 2026
HA
NYSE · HAE
Haemonetics Corporation
Healthcare · Medical - Instruments & Supplies
$119.65
Down-$0.14 (-0.12%)
Updated Nov 1, 2026, 7:40 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.12B
- P/E ratio
- 23.87
- Dividend yield
- 0.00%
- 52-week range
- $49.00 – $123.77
- Volume
- 453.35K
- Avg. volume
- 976.76K
Price performance · HAE
HAE price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
HAE closed at $119.65 after 20 trading sessions, up 14.30% for the selected period.
- Last close
- $119.65
- Period change
- +14.30%
- Period low
- $101.71
- Period high
- $122.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $120.50 | $120.50 | $118.395 | $119.65 | 453.35K |
| Oct 29, 2026 | $118.85 | $120.54 | $117.97 | $119.79 | 558.54K |
| Oct 28, 2026 | $119.40 | $120.79 | $117.71 | $118.32 | 501.82K |
| Oct 27, 2026 | $118.69 | $121.9099 | $117.70 | $119.97 | 900.89K |
| Oct 26, 2026 | $118.62 | $119.43 | $117.49 | $119.19 | 469.74K |
| Oct 23, 2026 | $115.50 | $119.20 | $115.4924 | $118.51 | 777.38K |
| Oct 22, 2026 | $117.70 | $118.68 | $116.07 | $116.16 | 365.13K |
| Oct 21, 2026 | $117.49 | $119.14 | $116.65 | $117.11 | 843.47K |
| Oct 20, 2026 | $119.50 | $120.50 | $117.205 | $118.21 | 585K |
| Oct 19, 2026 | $118.07 | $119.8199 | $117.00 | $118.73 | 392.22K |
| Oct 16, 2026 | $121.83 | $121.84 | $118.1914 | $118.28 | 471.52K |
| Oct 15, 2026 | $122.20 | $122.46 | $118.65 | $121.29 | 747.65K |
| Oct 14, 2026 | $121.81 | $122.53 | $119.55 | $121.11 | 592.14K |
| Oct 13, 2026 | $122.80 | $123.77 | $121.045 | $121.72 | 829.19K |
| Oct 12, 2026 | $118.70 | $122.24 | $118.355 | $122.06 | 895.09K |
| Oct 9, 2026 | $119.81 | $121.1925 | $116.515 | $118.69 | 1.25M |
| Oct 8, 2026 | $115.00 | $121.00 | $111.66 | $119.47 | 2.78M |
| Oct 7, 2026 | $103.48 | $104.02 | $101.315 | $101.71 | 625.58K |
| Oct 6, 2026 | $104.92 | $105.58 | $102.80 | $103.52 | 542.05K |
| Oct 5, 2026 | $104.29 | $106.26 | $103.645 | $104.68 | 652.65K |
Latest HAE news
The latest Smart Investors Daily articles mentioning HAE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HAE research
Overview
Company profile and research snapshot.
Company profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $82.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | Mizuho | Outperform | — |
| Oct 9, 2026 | Barrington Research | Outperform | — |
| Oct 8, 2026 | BTIG | Buy | — |
| Sep 17, 2026 | Citigroup | Buy | — |
| Sep 3, 2026 | Raymond James | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Haemonetics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 96.3%, reaching $118.21 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo · Oct 19, 2026
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition
Benzinga · Oct 19, 2026
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
